ABO Group Test

Most people learn their blood type and file it away as a transfusion detail. But your ABO group quietly influences how easily your blood clots, how your immune system handles certain infections, and even your baseline risk for heart attack and stroke. These effects are modest for any single person, yet they are consistent across studies involving millions of participants.

Knowing your ABO type is a one-time test with lifelong relevance. It does not change over your lifetime, so a single result gives you a permanent piece of your risk profile. The value is not in the label itself but in what it tells you about which other risks to watch more closely.

What Your Blood Type Actually Is

Your ABO group is determined by a gene on chromosome 9 that builds an enzyme called a glycosyltransferase. That enzyme attaches specific sugar molecules to precursor chains on the surface of your red blood cells, platelets, blood vessel walls, and tissues throughout your body, including your gut lining, kidneys, and lungs. If the enzyme adds one type of sugar, you express the A antigen. A different sugar produces the B antigen. If you inherit both versions, you are type AB. If you inherit neither functional version, you are type O, which means you carry the unmodified precursor (called the H antigen) instead.

These surface sugars do more than label your red blood cells. They change how a key clotting protein called von Willebrand factor (VWF) behaves in your bloodstream. People with type O blood clear VWF faster, so they naturally have lower levels. People with types A, B, or AB keep VWF circulating longer, which means their blood clots more readily. In a classic study of over 1,000 healthy individuals, type O individuals had VWF levels roughly 25% of the way up the normal scale, while type AB individuals averaged about 64% higher.

Blood Clots and Heart Disease

The clotting difference between type O and non-O blood types is the most well-established health consequence of ABO. Non-O types (A, B, and AB) carry roughly twice the risk of venous blood clots compared to type O. This includes deep vein thrombosis (blood clots in the legs) and pulmonary embolism (clots that travel to the lungs). The higher VWF and clotting factor VIII levels in non-O individuals are the primary explanation.

Heart disease follows a similar pattern. A meta-analysis pooling data from multiple large studies found that blood group A and non-O types are both risk factors for coronary artery disease, with group A carrying a somewhat stronger association than the broader non-O category. In a study of 1,180 people who had a heart attack caused by a complete blockage of a coronary artery (called a STEMI), non-O blood types were associated with higher clot burden in the blocked artery and worse short-term and long-term survival.

A large UK Biobank analysis of over 400,000 people confirmed these patterns at scale: blood groups A and B were linked to increased risk of blood clots, while also being associated with lower rates of high blood pressure, a finding that initially seems contradictory. The explanation is that ABO influences multiple systems independently. Higher clotting tendency and lower blood pressure are not mutually exclusive. They operate through different biological pathways.

If you are type A, B, or AB, this does not mean heart disease is inevitable. It means your baseline clotting tendency is slightly higher, which makes other modifiable risk factors (cholesterol, blood pressure, smoking, blood sugar) worth managing more aggressively. If you are type O, you have a relative advantage in this area, but it does not replace the need for standard cardiovascular screening.

Infection Susceptibility

Your ABO type also shapes how your immune system interacts with certain pathogens. The surface sugars on your cells can serve as docking points for viruses and bacteria, and the natural antibodies your body makes against the ABO antigens you do not carry (for example, type O people make antibodies against both A and B antigens) may offer some passive protection.

During the COVID-19 pandemic, multiple meta-analyses found that type A was associated with higher infection risk, while type O was associated with lower risk. One meta-analysis found that types A, B, and AB all carried higher COVID-19 infection risk compared to type O. In critically ill COVID-19 patients, those with blood group A or AB were more likely to need mechanical ventilation and had longer ICU stays.

For malaria, a meta-analysis found that non-O blood types have higher odds of severe disease caused by Plasmodium falciparum, the deadliest malaria parasite. Types A and B appear more vulnerable to severe malarial anemia specifically. For hepatitis B, a meta-analysis found that type B carried about 8% lower risk of infection, while type O carried about 12% higher risk in areas where hepatitis B is common. For HIV, a meta-analysis found that type AB carriers had roughly 19% higher infection risk compared to non-AB types.

Cancer Risk

A large meta-analysis combining epidemiological and genetic evidence found that non-O blood types, especially type A, are associated with increased risk of several cancers: stomach, pancreas, colorectal, liver, ovarian, cervical, bladder, and breast. The effect sizes are modest. Having type A does not dramatically change your cancer odds, but it does add a small, consistent push in the wrong direction across multiple cancer types.

For pancreatic cancer specifically, the ABO association may be modified by another genetic factor: your secretor status, which determines whether ABO antigens appear on mucosal surfaces and in bodily fluids. A study of over 19,000 individuals found that the link between ABO type and pancreatic cancer was stronger among people who are secretors. ABO type alone was not a reliable predictor of survival after pancreatic cancer surgery, though it may influence response to specific chemotherapy regimens.

Longevity

A study of 165 Italian centenarians (people who lived past 100) found that type O was significantly more common among them than in the general blood donor population: 56% of centenarians were type O compared to 44% of donors. The advantage was especially pronounced in men. The likely explanation is not a single protective mechanism but rather the cumulative benefit of lower clotting risk and modestly reduced cancer susceptibility over a very long lifespan.

What Your Blood Type Does Not Tell You

ABO is one genetic risk factor among many. The risk differences it creates are real but modest, typically shifting your odds by 10% to 30% for any given condition. It is not a diagnostic tool and should never be used alone to make clinical decisions. A large study of nearly 30,000 critically ill patients in intensive care units found no significant difference in overall mortality or organ support requirements across ABO types. Similarly, a meta-analysis of assisted reproduction outcomes found no meaningful link between ABO type and ovarian reserve, pregnancy rates, or miscarriage rates. And a meta-analysis across multiple datasets found no association between ABO type and major depression.

The practical lesson: your blood type adds nuance to your overall risk picture, but it does not override standard risk factors like cholesterol, blood pressure, blood sugar, smoking status, and family history.

How ABO Blood Type Is Tested

Standard ABO typing uses a simple blood test where your red blood cells are mixed with antibodies against A and B antigens (forward typing) and your serum is mixed with known A and B red blood cells (reverse typing). Results are available quickly and are highly accurate for the vast majority of people. Rare individuals carry weak variants of the A or B antigen that standard testing may misclassify. When higher precision is needed, such as for kidney transplant donor matching, genetic sequencing of the ABO gene can identify these subtle variants.

How ABO Affects Other Lab Results

Because ABO influences VWF levels and clotting factors, it can shift the results of certain coagulation tests. A study of 9,600 healthy Chinese adults found that type O individuals had slightly longer aPTT (activated partial thromboplastin time, a measure of how quickly blood clots in a test tube) compared to non-O types. Differences in prothrombin time and INR (international normalized ratio) were statistically significant but very small.

VWF levels vary substantially by blood type. In a study of over 1,000 healthy individuals, mean VWF levels were about 75 arbitrary units in type O, 106 in type A, 117 in type B, and 123 in type AB. This means type O individuals are over-represented among people diagnosed with mild bleeding disorders like type 1 von Willebrand disease, while type AB individuals may have a genuine clotting deficiency masked by their naturally higher VWF baseline. If you are being evaluated for unexplained bleeding or bruising, your doctor should factor in your ABO type when interpreting VWF results.

For routine blood counts (CBC), two large studies from Qatar and Oman found no clinically meaningful differences across ABO types. Age and sex matter for CBC interpretation; ABO type does not.

Tracking and Next Steps

Unlike most biomarkers, your ABO type does not change, so there is no need to retest. One accurate result gives you a permanent data point. The value of knowing your type lies in how you use it alongside your other lab results. If you are type A, B, or AB, consider pairing your result with a deeper look at your cardiovascular risk: ApoB (apolipoprotein B, a measure of the number of cholesterol-carrying particles in your blood), hs-CRP (high-sensitivity C-reactive protein, a marker of inflammation), and a standard lipid panel together give a much richer picture of whether your slightly elevated baseline clotting risk is compounded by other factors.

If your ABO result is type O, you still benefit from standard cardiovascular screening, but you can take some comfort that your clotting system is working with a lower baseline. If you are being evaluated for a bleeding tendency, make sure whoever reads your VWF results knows your blood type.

If you already know you have cardiovascular risk factors (high cholesterol, family history of heart disease, diabetes), a non-O blood type is another reason to manage those factors more tightly rather than take a wait-and-see approach. The combination of a modest genetic push toward clotting plus modifiable risk factors is where real prevention happens.